| Michaela Lee, MD | |
|
755 E Mcdowell Rd Fl 2, Phoenix, AZ 85006-2506 | |
| (602) 521-3201 | |
| (602) 521-3246 |
| Full Name | Michaela Lee |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 14 Years |
| Location | 755 E Mcdowell Rd Fl 2, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396062386 | NPI | - | NPPES |
| 251878 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 53573 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner - University Medical Center Phoenix | Phoenix, AZ | Hospital |
| Banner Gateway Medical Center | Gilbert, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Banner - University Physician Specialists Llc | 5991008054 | 233 |
| Bhsm Rehabilitation Llc | 2062773138 | 1258 |
News Archive
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths - in some cases, even how aggressively to test - along with a push for more of the informed-choice programs.
Routine clinical use of immunoassays, a type of blood test for measuring antigen-specific IgE or IgG antibodies, is not recommended as a primary means of assessing environmental fungal exposure or its harmful effects according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.
› Verified 3 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths - in some cases, even how aggressively to test - along with a push for more of the informed-choice programs.
Routine clinical use of immunoassays, a type of blood test for measuring antigen-specific IgE or IgG antibodies, is not recommended as a primary means of assessing environmental fungal exposure or its harmful effects according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.
› Verified 3 days ago
| Entity Name | Banner - University Hospital Based Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750751566 PECOS PAC ID: 1052614294 Enrollment ID: O20160122000508 |
News Archive
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths - in some cases, even how aggressively to test - along with a push for more of the informed-choice programs.
Routine clinical use of immunoassays, a type of blood test for measuring antigen-specific IgE or IgG antibodies, is not recommended as a primary means of assessing environmental fungal exposure or its harmful effects according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.
› Verified 3 days ago
| Entity Name | Banner - University Physician Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437529245 PECOS PAC ID: 5991008054 Enrollment ID: O20160122001476 |
News Archive
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths - in some cases, even how aggressively to test - along with a push for more of the informed-choice programs.
Routine clinical use of immunoassays, a type of blood test for measuring antigen-specific IgE or IgG antibodies, is not recommended as a primary means of assessing environmental fungal exposure or its harmful effects according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michaela Lee, MD 755 E Mcdowell Rd Fl 2, Phoenix, AZ 85006-2506 Ph: (602) 521-3201 | Michaela Lee, MD 755 E Mcdowell Rd Fl 2, Phoenix, AZ 85006-2506 Ph: (602) 521-3201 |
News Archive
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.
The Associated Press/Arizona Republic: "It's an unthinkable notion for a generation raised on the message that early cancer detection saves lives, but specialists say more tumors actually are being found too early. That is raising uncomfortable questions about how aggressively to treat early growths - in some cases, even how aggressively to test - along with a push for more of the informed-choice programs.
Routine clinical use of immunoassays, a type of blood test for measuring antigen-specific IgE or IgG antibodies, is not recommended as a primary means of assessing environmental fungal exposure or its harmful effects according to a report published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.
› Verified 3 days ago
Curtis A Dickman, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3632 Fax: 602-406-4187 | |
Dr. Naresh P Patel, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
James Zhou, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 350 W Thomas Rd, Phoenix, AZ 85013 Phone: 602-406-4958 | |
Dr. Mark Edward Oppenlander, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 19636 N 27th Ave Ste 203, Phoenix, AZ 85027 Phone: 235-625-0506 Fax: 623-562-5051 | |
Dr. Erik I Curtis, M.D., M.S. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2222 E Highland Ave Ste 222, Phoenix, AZ 85016 Phone: 602-603-0971 | |
Dr. Michael T Lawton, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3489 Fax: 602-406-4402 | |
Dr. Jonathan Seth Hott, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 9225 N 3rd St, Suite 100, Phoenix, AZ 85020 Phone: 602-943-4509 Fax: 602-943-0348 |